What is the monoclonal antibody for CIDP? Understanding targeted therapies
•
5 min read
In a significant development for the CIDP community, the U.S. Food and Drug Administration (FDA) approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in June 2024, making it the first and only neonatal Fc receptor (FcRn) blocking monoclonal antibody for CIDP. This milestone provides a new, targeted therapeutic option for adults living with chronic inflammatory demyelinating polyneuropathy.
